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Hodgkin lymphoma (HL) prognostic models based on factors measured at time of autologous hematopoietic
cell transplantation (AHCT) are limited by small sample sizes. Models based on information at diagnosis are
often not uniformly collected or available at transplantation. We propose an easily implementable prognostic
model for progression-free survival (PFS) post-AHCT based on factors available at transplantation in a large
international cohort of HL patients. The outcomes of 728 AHCT recipients for relapsed/refractory HL were
studied. Patients were randomly selected for model development (n ¼ 337) and validation (n ¼ 391). The
multivariate model identiﬁed 4 major adverse risk factors at the time of AHCT with the following relative
weights: Karnofsky performance score <90 and chemotherapy resistance at AHCT were each assigned 1
point, whereas at least 3 chemotherapy regimens pre-AHCT and extranodal disease at AHCT were each
assigned 2 points. Based on the total score summed for the 4 adverse risk factors, 3 risk groups were iden-
tiﬁed: low (score ¼ 0), intermediate (score ¼ 1 to 3), or high (score ¼ 4 to 6). The 4-year PFS for the low- (n ¼
176), intermediate- (n ¼ 261), and high- (n ¼ 283) risk groups were 71% (95% conﬁdence interval [CI], 63% to
78%), 60% (95% CI, 53% to 66%), and 42% (95% CI, 36% to 49%), respectively. The prognostic model was validated
in an independent cohort. The Center for International Blood and Marrow Transplant Research model is based
on factors easily available at the time of AHCT and discriminates patients with favorable post-AHCT outcomes
as well as an intermediate-risk group. This model should assist in the prospective evaluation of alternative
treatment strategies.
 2013 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION assessed at time of AHCT instead of at diagnosis [18-23]. We
Autologous hematopoietic cell transplantation (AHCT) is
standard therapy for relapsed and refractory Hodgkin
lymphoma (HL) [1,2]. Although survival post-AHCT for HL
has improved signiﬁcantly over time [3,4], the primary cause
of AHCT failure is due to HL relapse or progression [5]. To
date, efforts to improve disease control post-AHCT for HL
have had limited success [6-10].
Several validated prognostic models have been developed
to predict treatment outcomes for HL patients and to help
guide initial treatment decisions. However, these models are
targeted for prognosis of newly diagnosed HL patients and
were not designed for prognosis of HL patients after relapse
or for assessment of AHCT outcomes [11-17]. There are 6
published prognostic models of progression-free survival
(PFS) for relapsed/refractory HL based on risk factorsedgments on page 1743.
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13.09.018could not attempt to validate 3 of these 6 models due to
either a high rate of missing data (diagnostic albumin,
hemoglobin, white blood cell count, absolute lymphocyte
count, duration of ﬁrst complete remission) or data not
collected (eg, relapse in a previously radiated ﬁeld) on the
standard Center for International Blood and Marrow Trans-
plant Research (CIBMTR) report forms for HL [18-20]. We
were able to independently validate the other 3 published
models [21-23] that differentiated low-and high-risk groups,
but all lacked discrimination of an intermediate-risk group
[24] Two additional prognostic models have assessed patient
characteristics at time of relapse to guide salvage therapy
options [25,26]. We sought to develop and validate a prog-
nostic model using factors that are easily and widely avail-
able at time of AHCT in the largest cohort of HL patients
treated with AHCT.
METHODS
CIBMTR
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry and the National Marrow Donor Program, established in
2004, that comprises a voluntary working group of more than 450 trans-
plantation centers worldwide that contribute detailed data on consecutive
allogeneic and autologous hematopoietic cell transplants to a statistical
center at the Medical College of Wisconsin in Milwaukee and the National
Marrow Donor Program Coordinating Center in Minneapolis. Participating
centers are required to report all transplants consecutively; compliance is
monitored by on-site audits. Patients are followed longitudinally, witherican Society for Blood and Marrow Transplantation.
Table 1
Patient Characteristics of AHCT recipients with HL
Variable N (%)
Number of patients 728
Number of centers 162
Age at transplant, y
10 4 (1)
11-20 98 (13)
21-30 225 (31)
31-40 197 (27)
41-50 111 (15)
51-60 50 (7)
61 43 (6)
Age at transplant, y, median (range) 33 (7-74)
Male gender 434 (60)
Karnofsky performance score at AHCT
<90 192 (26)
HL histology
Nodular sclerosis 542 (74)
Mixed cellularity 100 (14)
Lymphocyte-rich 47 (6)
Lymphocyte depleted 8 (1)
Otherdnot speciﬁed 31 (4)
HL stage at diagnosis
I 41 (6)
II 300 (42)
III 219 (30)
IV 158 (22)
Extranodal involvement at diagnosis 246 (34)
B symptoms at diagnosis 414 (57)
Number of pre-AHCT chemotherapy regimens
1 53 (7)
2 381 (53)
3 201 (28)
4 75 (10)
5 17 (2)
Interval from diagnosis to ﬁrst CR, mo, median (range) 7 (<1-123)
Interval from ﬁrst CR to transplant, mo, median (range) 16 (<1-136)
Interval from last CR to transplant, mo, median (range) 6 (<1-117)
Disease status at AHCT
Chemotherapy-sensitive relapse 263 (36)
CR 200 (27)
First partial response (no prior CR) 136 (19)
Chemotherapy-resistant/unknown relapse 87 (12)
Primary induction failure (no prior CR, less than
partial response to induction)
42 (6)
Chemotherapy-sensitivity at AHCT
Sensitive 579 (80)
Resistant 119 (16)
Untreated/not assessable 30 (4)
LDH at AHCT
Normal 426 (59)
Abnormal 196 (27)
Missing 106 (15)
Extranodal involvement at AHCT 139 (19)
5 cm mass before AHCT 71 (27)
12 mo from diagnosis to AHCT 602 (83)
Interval from diagnosis to AHCT, mo, median (range) 22 (3-368)
Conditioning regimen
BEAM or similar 517 (71)
CBV or similar 98 (13)
BuMel or BuCy 34 (5)
TBI-based 28 (4)
Others 19 (3)
Cy þ thiotepa or similar 14 (2)
Melphalan alone 18 (2)
Year of transplant
1996-1999 437 (60)
2000-2003 146 (20)
2004-2007 145 (20)
Median follow-up of survivors, mo 43 (1-131)
LDH indicates lactate dehydrogenase; CR, complete remission; PR, partial
remission; BEAM, BCNU, etoposide, Ara-C, melphalan; CBV, cyclophospha-
mide, BCNU, etoposide; BuMel, busulfan, melphalan; BuCy, busulfan,
cyclophosphamide; TBI, total body irradiation.
Table 2
Multivariate Model for the Risk of Treatment Failure (1-PFS or the Risk of
Relapse or Death)
Variable RR of Treatment
Failure (95%
Conﬁdence Interval)
P Score
Number of prior chemotherapy
regimens: 3-5 vs. 1-2
1.80 (1.31-2.47) .0003 2
Extranodal involvement before
AHCT: yes vs. no
1.77 (1.24-2.53) .0018 2
Karnofsky score before AHCT:
<90 vs. 90-100
1.47 (1.04-2.07) .0275 1
Chemotherapy-sensitivity pre-
AHCT: resistant vs. sensitive
1.45 (1.01-2.07) .0440 1
P values of additional risk factors considered in the model are as follows: HL
histology (P ¼ .6295), B symptoms at diagnosis (P ¼ .1516), relapse/primary
induction failure at AHCT (P ¼ .2025), elevated lactate dehydrogenase at
AHCT (P¼ .1319),5 cmmass at AHCT (P¼ .9553), age>40 (P¼ .2700), and
<12 months from diagnosis to transplant (P ¼ .2433).
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of submitted data, and on-site audits of participating centers ensure data
quality. Observational studies conducted by the CIBMTR are performed in
compliance with the Privacy Rule (HIPAA) as a Public Health Authority and
in compliance with all applicable federal regulations pertaining to the
protection of human research participants as determined by continuous
review of the Institutional Review Boards of the National Marrow Donor
Program and the Medical College of Wisconsin since 1985.
Study Population
The selection criteria for this study were as follows: HL patients
receiving a ﬁrst AHCT from 1996 to 2007 reported to the CIBMTR (N¼ 1026),
excluding HL patients in ﬁrst complete remission pre-AHCT (n ¼ 160
excluded), those with a planned second transplant (n ¼ 9 excluded), and
those with missing data on potential prognostic factors (n ¼ 129 excluded).
Thus, the study cohort yielded 728 AHCT recipients with relapsed or
refractory HL with complete data reported to the CIBMTR. Eight cases were
missing information on relapse post-AHCT and are excluded from analyses
of PFS but are included in analyses of overall survival.
Statistical Methods
Progressionwas deﬁned as an increase of25% in the sites of lymphoma
or development of new sites of lymphoma. Relapse was deﬁned as recur-
rence of lymphoma after a complete response. Patients alive without
evidence of disease relapse or progression were censored at last follow-up,
and the PFS event was summarized by a survival curve.
The study cohort was randomly split into 2 datasets, 1 for model
development (n ¼ 337) and 1 for model veriﬁcation (n ¼ 391). A Cox
regression method was used to identify potential risk factors associated
with treatment failure (failure event of PFS), and the model development
cohort was used to build a forward stepwise model with P¼ .05 to enter and
remove factors from the model. The results were then conﬁrmed using
a backward elimination procedure. The following risk factors were consid-
ered in the model-building procedure: 3 chemotherapy regimens before
AHCT, Karnofsky performance score at AHCT (<90 versus 90), age > 40
versus 40, HL histology, B symptoms at diagnosis, relapse/primary
induction failure at AHCT, chemotherapy-resistant disease at AHCT, elevated
lactate dehydrogenase at AHCT, extranodal involvement at AHCT, 5 cm
mass at AHCT, and <12 months from diagnosis to transplant.
Based on the ﬁnal multivariate model of signiﬁcant prognostic factors,
each factor was assigned a weighted score based on relative risk (RR) esti-
mates (see Table 2). The score for each of the 4 signiﬁcant prognostic factors
was summed to a total score that ranged from 0 to 6. Distribution of patients
by total risk score was as follows: 98 patients had a total risk score of
0 (reference category), 51 patients had a total risk score of 1 (RR range, 4.3 to
4.4),101 patients had a total risk score of 2 (RR range, 5.8 to 18.5), 45 patients
had a total risk score of 3 (RR range, 25.0 to 26.3), 23 patients had a total risk
score of 4 (RR range, 35.5 to 112), and 19 patients had a total risk score of 5 or
6 (RR,>150). Based on the range of RR and the distribution of patients across
the total risk score categories, we classiﬁed each patient into 1 of 3 prog-
nostic risk groups: low-risk group (score ¼ 0), intermediate-risk group
(score¼ 1 to 3), or high-risk group (score¼ 4 to 6). Once the ﬁnal model was
deﬁned, it was then tested in the independent model validation cohort. All
Table 3
Predicting Treatment Failure by the CIBMTR Prognostic Model: Model Development Cohort, Model Validation Cohort, and Both Cohorts Combined
Risk Group Model Development Cohort Model Validation Cohort Combined Cohort
N RR (95% CI) P N RR (95% CI) P N RR (95% CI) P
Low risk 98 1.00 <.0001* 131 1.00 .0019* 229 1.00 <.0001
Intermediate risk 197 1.46 (.98-2.18) .0639 220 1.33 (.93-1.89) .1178 417 1.39 (1.07-1.81) .0144
High risk 42 3.37 (2.07-5.50) <.0001 40 2.57 (1.61-4.09) <.0001 82 2.95 (2.11-4.13) <.0001
* 2 df test.
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Cary, NC).RESULTS
Patient characteristics are summarized in Table 1. Seven-
hundred twenty-eight patients were reported from 162
centers worldwide.
The ﬁnal multivariate model of signiﬁcant risk factors is
summarized in Table 2. A poor Karnofsky performance score
(<90) or chemotherapy-resistant disease pre-AHCT yielded
RR estimates of 1.47 and 1.45, respectively, and were assigned
aweighted score of 1. Three or more chemotherapy treatment
regimens before AHCT and presence of extranodal disease at
time of AHCT had higher RR estimates of 1.8 and 1.77,
respectively, andwere assigned aweighted score of 2. Patients
with no risk factors (score ¼ 0) were assigned to the low-risk
group (n ¼ 98), those with a score of 1 to 3 were assigned to
an intermediate-risk group (n ¼ 197), and those with a score
of 4 to 6 were assigned to a high-risk group (n ¼ 42).
Table 3 summarizes the prognostic model’s performance
in the development and validation datasets. We identiﬁed 3
distinct risk groups, including an intermediate-risk group.
Statistical signiﬁcance was reached for the intermediate-risk
group after combining the model development and valida-
tion datasets (Figures 1 and 2). The 4-year PFS estimates and
95% conﬁdence intervals for the low-, intermediate-, and
high-risk groups for the entire cohort were 71% (63% to 78%),
60% (53% to 66%), and 42% (36% to 49%), respectively. At
a median follow-up of 43 months, the primary causes of
death post-AHCT were recurrent HL (n ¼ 154, 64% of all
deaths), organ failure (n ¼ 28, 12%), interstitial pneumonitis
or adult respiratory distress syndrome (n ¼ 15, 6%), secondFigure 1. PFS for the model development, momalignancy (n ¼ 8, 3%), hemorrhage (n ¼ 5, 2%), infection
(n ¼ 4, 2%), or other/missing (n ¼ 28, 12%).
The rate of a second allogeneic HCT after failed AHCT was
9 of 229 (4%) for the low-risk, 16 of 417 (4%) for the
intermediate-risk, and 4 of 82 (5%) for the high-risk groups.
Hence, the rate of second allogeneic HCT to rescue a failed
AHCT did not differ by risk group. In addition, it did not affect
the PFS curves for our analysis because all patients had an
event (disease progression) that was included in the PFS
analysis and that occurred before the allogeneic HCT. Hence,
the attempted rescue using an allogeneic HCT is not reﬂected
in the PFS analysis.DISCUSSION
To our knowledge, this represents the largest multicenter
international cohort of AHCT for relapsed/refractory HL.
Our large dataset helped us develop a robust prognostic
model that identiﬁes 3 different risk groups. The highest risk
group had a 42% PFS at 4 years and identiﬁed those with
the lowest likelihood of cure from AHCT. They should be
considered candidates for trials of additional or alternative
therapy, which could include maintenance/consolidation
therapy post-AHCT or alternative therapies such as bren-
tuximab vedotin or reduced-intensity allogeneic HCT [27,28].
A randomized multicenter trial of brentuximab vedotin after
AHCT is ongoing in patients classiﬁed as “high risk” accord-
ing to our prognostic model and may provide evidence of
a new treatment strategy for relapsed/refractory HL [29].
Three previously published AHCT prognostic models all
yielded 3 risk factors, each of which were evenly weighted
[21-23]. One model discriminated 2 risk groups (low, high)
[21], whereas the other 2 models discriminated 3 risk groupsdel validation, and combined cohorts.
Figure 2. Overall survival for the model development, model validation, and combined cohorts.
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to validate the prognostic signiﬁcance of the intermediate-
risk groups in these 2 models [24]. In contrast, our new
prognostic model contains 4 risk factors that were given
a weighted score or 1 or 2 based on the RR estimate.
Summing the scores across all risk factors generated a ﬁnal
score to assign patients to a risk category. One risk factor in
our model (chemotherapy-resistant disease pre-AHCT) was
a signiﬁcant risk factor in all 3 prior models, whereas the
other 3 risk factors were reported in only 1 or 2 of the prior
models. Hence, all 4 of our risk factors were previously
reported as prognostic of PFS after AHCT. The large size of
our cohort enabled us to reﬁne and enhance these prior
models and to signiﬁcantly distinguish and validate an
intermediate-risk group for overall survival. However, the
intermediate-risk group was only signiﬁcantly different from
the low- and high-risk groups for PFS after combining both
the development and validation cohorts.
Recent studies reported the value of pretransplant posi-
tron emission tomography (PET) functional imaging, which
provides prognostic information in the setting of AHCT for HL
[30-33]. PET was not approved for HL staging until 2004 in
the United States, which is near the end of our cohort (2006).
Most patients in our study (73%) were not in complete
remission before AHCT and therefore should have been PET-
positive. Even in more recently treated patients from 2007 to
2010 in the same registry, about 77% had a PET scan pre-
AHCT and the majority of those (81%) were positive,
leaving few patients with a negative PET pre-AHCT to eval-
uate in a multivariate prognostic model. However, our
attempt was to tease out higher risk groups in patients with
detectable disease by standard computed tomography
criteria; hence, the addition of PET scan information would
not be discriminatory in this setting. Although our prog-
nostic model is inexpensive and easy to use, especially in
countries where there is limited access to PET imaging, the
future use of PET scans may further deﬁne extranodal
involvement and chemotherapy sensitivity pre-AHCT and
could further reﬁne our model.
A signiﬁcant proportion of patients were missing lactate
dehydrogenase at diagnosis and sizing of tumor masses
during therapy. These reﬂect the importance of obtaining
a lactate dehydrogenase measurement by all oncologists and
the need for a standardized approach to reading and sizing
tumor masses during therapy. Finally, 84% of patients whowere not in complete remission pre-AHCT were missing
information on whether post-AHCT radiation therapy was
planned or not. Therefore, it is unknown if post-AHCT radi-
ation, or any other planned post-AHCT treatment, can
improve prognosis or response rates or can overcome the
pre-AHCT poor risk factors. It is also unknown if post-AHCT
radiation therapy may have been applied differently to the
3 prognostic groups. However, this question can only be
answered in prospective trials, and pre-AHCT prognostic
models are crucial in the design and stratiﬁcation of such
approaches.
Our model is based on a large multicenter international
cohort of HL patients undergoing AHCT and uses easily
collectible information at the time of AHCT. We expect these
features to improve its applicability and generalizability. We
expect this model to assist clinicians in obtaining important
prognostic features during the pre-AHCT timeline to identify
those patients who may need additional post-AHCT therapy,
alternative transplant, or novel approaches.
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